2011 Predictions (or at worse, my wish list)
1- Merck files a Ridaforolimus NDA by no later than July 30th 2011
2- FDA approves Ridaforloimus by 4th quarter 2011 or first quarter 2012
3- Ariad partners Ponatinib in Asia before years end
4- Ariad announces a new compound before years end
5- Ponatinib clinical trial is fully enrolled by August 15th 2011
6- Before years end, Ariad reveals preliminary data on Pona clinical trial
7- Ariad initiates a Phase 1 clinical trial for 113 by July 15th 2011
8- Ariad shares trade at $20.00 a share (some time before Christmas)
9- Ten (10) of the Ariad message board member, meet in Manhattan for a lobster dinner and party, prior to New Year's Eve
As usual this is JMHO,
Barry
